(Alliance News) - Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with autoimmune disorder primary immune thrombocytopenia or ITP. Read More
Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31. "This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients," Hutchmed says. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein, it explains. Read More
Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid. Read More
(Alliance News) - Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it believes could fill significant clinical gaps. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib. Read More
(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration. Read More
(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later. Read More
(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. Read More
(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership. Read More
(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city. Read More
(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision. Read More
Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed. Read More
(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib. Read More
(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer. Read More